What is best treatment for fibromyalgia

The best treatment for fibromyalgia is not a single pill. It is a layered approach where non-drug strategies—exercise, education, and psychological support—come first, and drugs are used sparingly for the minority who get clear benefit.

The evidence here is dominated by manufacturer-funded trials of pregabalin (Lyrica) and duloxetine (Cymbalta). A 2020 BMJ review of pregabalin for fibromyalgia, pooling three trials with 1,122 patients, found that only about 24% of people on the drug got at least 50% pain relief, compared to 15% on placebo [6]. That is a number needed to treat (NNT) of 11: you have to treat 11 people for one to get that level of relief. The number needed to harm (NNH) was 5.9, meaning for every six people treated, one had an adverse event bad enough to matter [6]. The most common side effects were dizziness, drowsiness, and weight gain [5, 6]. A 2021 meta-analysis of six pregabalin trials confirmed the modest effect [7]. Duloxetine 60 mg works about the same way: a Cochrane review found it effective for pain at 12 weeks, but the effect is small and dropout rates from side effects were higher than placebo [3].

Non-drug treatments look better. A 2013 Cochrane review found that structured aerobic exercise—land or water, mild to moderate, two to three times a week—improves quality of life and modestly reduces pain [3, 4]. A 2016 randomized trial showed that exercise-based motivational interviewing improved physical function and pain at 36 weeks, but only in patients not using opioids; opioid users got no benefit [1]. Cognitive behavioral therapy (CBT) improves depression and pain levels, though the effect on pain is small [3]. A 2019 meta-analysis of low-level laser therapy found it improved pain, fatigue, and stiffness compared to placebo, but adding it to exercise gave no extra benefit [2].

The drugs are not worthless, but their effects are modest and their side effects are common. The non-drug options—exercise, CBT, education—have fewer downsides and comparable or better evidence for improving function and quality of life. The 2022 narrative review in Rheumatology recommends a multimodal approach that starts with non-pharmacologic care and adds drugs only when needed [3].

My call: start with graded exercise and CBT, not a prescription. Add pregabalin or duloxetine only if pain remains disabling after a fair trial of non-drug therapy, and stop them if clear benefit is not seen within a few weeks.

Confidence: moderate. The drug trials are numerous and consistent, but manufacturer-funded and show only modest benefit. The exercise and CBT evidence is solid but limited by adherence and study quality.